CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ — Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS),
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca’s eplontersen, an investigational therapy for the treatment of
Ionis to hold fourth quarter and full year 2023 financial results webcast
Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21 st at 11:30 a.m.
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks Donidalorsen demonstrated a favorable safety and tolerability profile Ionis is preparing to submit a New Drug Application
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif. , Jan. 8, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company’s 2023 achievements and previewed a number of important milestones expected